Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

1. Camidge, D.R.
2. Kim, H.R.
3. Ahn, M.-J.
4. Yang, J.C.H.
5. Han, J.-Y.
6. Hochmair, M.J.
7. Lee, K.H.
8. Delmonte, A.
9. Garcia Campelo, M.R.
10. Kim, D.-W.
11. Griesinger, F.
12. Felip, E.
13. Califano, R.
14. Spira, A.I.
15. Gettinger, S.N.
16. Tiseo, M.
17. Lin, H.M.
18. Liu, Y.
19. Vranceanu, F.
20. Niu, H.
21. Zhang, P.
22. Popat, S.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.JTHO.2021.07.035 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus